{
    "body": "DX-88 is investigational name of which drug?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/18467921", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19093699", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18220151", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21481442", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14572819", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21760740", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16916274", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18613770"
    ], 
    "ideal_answer": [
        "DX-88 is investigational name of a drug Ecallantide, a 60-amino acid recombinant protein discovered through phage display technology, that is a highly specific, potent inhibitor of human plasma kallikrein that has been used successfully in the treatment of patients experiencing acute hereditary angioedema attacks."
    ], 
    "exact_answer": [
        "Ecallantide"
    ], 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015507"
    ], 
    "type": "factoid", 
    "id": "54f1e031c409818c32000001", 
    "snippets": [
        {
            "offsetInBeginSection": 505, 
            "offsetInEndSection": 635, 
            "text": "Ecallantide (known as DX-88 previously), a potent and specific inhibitor of plasma kallikrein is an innovative medicinal product. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21760740", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 116, 
            "text": "Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase 3 studies.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21481442", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 661, 
            "offsetInEndSection": 992, 
            "text": "Several novel therapies have completed phase III trials in the US, including: (i) plasma-derived C1-INH replacement therapies (Berinert P and Cinryze); (ii) a recombinant C1-INH replacement therapy (conestat alfa; Rhucin); (iii) a kallikrein inhibitor (ecallantide [DX-88]); and (iv) a bradykinin-2-receptor antagonist (icatibant).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19093699", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 161, 
            "text": "Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18613770", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 315, 
            "offsetInEndSection": 403, 
            "text": "OBJECTIVE: Ecallantide (DX-88) is a potent and specific inhibitor of plasma kallikrein. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18613770", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 277, 
            "offsetInEndSection": 537, 
            "text": "DX-88 (ecallantide), a 60-amino acid recombinant protein discovered through phage display technology, is a highly specific, potent inhibitor of human plasma kallikrein that has been used successfully in the treatment of patients experiencing acute HAE attacks.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18467921", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 983, 
            "offsetInEndSection": 1204, 
            "text": "DX-88 or ecallantide, a potent and specific inhibitor of plasma kallikrein, achieved all primary and secondary efficacy end points in a placebo-controlled, double-blind, phase 3 study, with a second phase 3 study ongoing.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18220151", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 387, 
            "offsetInEndSection": 552, 
            "text": "DX-88 (ecallantide, Dyax Corp.) is a highly specific recombinant plasma kallikrein inhibitor that halts the production of bradykinin and can be dosed subcutaneously.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16916274", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 387, 
            "offsetInEndSection": 551, 
            "text": "DX-88 (ecallantide, Dyax Corp.) is a highly specific recombinant plasma kallikrein inhibitor that halts the production of bradykinin and can be dosed subcutaneously", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16916274", 
            "endSection": "abstract"
        }
    ]
}